[Biomarker for chemotherapy in patients with colorectal cancer].
Prognostic, predictive and safety biomarkers of chemotherapy for colorectal cancer have been reported. Recently, it was reported that KRAS mutation was present in 27-43% of patients, was associated with resistance to antibody against the epidermal growth factor receptor(EGFR), and showed a poorer survival in metastatic colorectal cancer. The search for biomarkers is therefore being conducted vigorously in parallel with a number of clinical trials that are currently being conducted for new drugs. We believe that future areas of research will include the establishment of clinical evidence through large-scale clinical trials and the standardization of analysis protocols.
Matsusaka
Satoshi
S
Division of Medical Oncology, Cancer Institute Ariake Hospital, Japan.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015415:Biomarkers